Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eVOLVE-02: volrustomig alone or with chemotherapy in advanced/metastatic solid tumors
2025-523947-36-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Jun 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, open-label trial of volrustomig in Esophageal Squamous Cell Carcinoma (ESCC) and pleural mesothelioma (2 arms), sponsored by AstraZeneca. Primary endpoints: Objective response rate and Adverse events and serious adverse events. Planned start Jun 2026; status: authorised.
02
Drugs
volrustomig
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)pleural mesothelioma
Beyond the preview
Go deeper on 2025-523947-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523947-36-00.